Placental growth factor may predict increased left ventricular mass index in patients with mild to moderate chronic kidney disease – a prospective observational study

BMC Nephrology

Vladimir Tesař³  Tomas Zima²  Ales Linhart¹  Hana Benáková²  David Ambrož¹  Amjad Bani-Hani¹  Eduard Němeček¹  Magdalena Hodková³  Blanka Míková⁴  Vilem Danzig¹  Marta Kalousová²  Martina Peiskerová² 

[1] 2nd Department of Medicine - Department of Cardiovascular Medicine First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic;Institute of Medical Biochemistry and Laboratory Medicine, First Faculty of Medicine, Charles University and General University Hospital, Prague, Czech Republic;Department of Nephrology, First Faculty of Medicine, Charles University, Prague, Czech Republic;Clinical Biochemistry, Haematology and Immunology, Na Homolce Hospital, Prague, Czech Republic

关键词: Placental growth factor (PlGF);    Left ventricular diastolic function;    Left ventricular hypertrophy;    Left ventricular mass index;    Extracellular newly identified RAGE-binding protein (EN-RAGE);    Echocardiography;    Chronic kidney disease;    Cardiovascular disease;   

Others  :  1082897
DOI  :  10.1186/1471-2369-14-142

 received in 2012-10-31, accepted in 2013-06-26,  发布年份 2013

【 摘 要 】

Background

Placental growth factor [PlGF) is a cardiovascular (CV) risk marker, which is related to left ventricle hypertrophy (LVH) in animal models. Currently there are no data available regarding the possible relationship of PlGF and the development of LVH or diastolic dysfunction in patients with chronic kidney disease (CKD) and the relationship of PlGF to other CV risk factors in CKD patients. The aim of our study was to determine the possible association of PlGF and several other CV risk markers to echocardiographic parameters in CKD population.

Methods

We prospectively examined selected laboratory (PlGF, fibroblast growth factor-23 -FGF23, vitamin D, parathyroid hormone, extracellular newly identified RAGE-binding protein - EN-RAGE, B-type natriuretic peptide - BNP) and echocardiographic parameters in 62 patients with CKD 2–4. Mean follow-up was 36 ±10 months. Laboratory and echocardiographic data were collected 2–3 times, at the shortest interval of 12 months apart. Multivariate regression analysis was used to detect independent correlations of variables.

Results

Increased left ventricular mass index (LVMI, g/m^2.7) was found in 29% patients with CKD 2–4, left ventricular (LV) diastolic dysfunction was detected in 74.1% patients (impaired LV relaxation in 43.5% patients and pseudonormal pattern in 30.6% patients). After 36 ± 10 months increased LVMI was found in 37.1% patients with CKD 2–4, LV diastolic dysfunction was detected in 75.8% patients (impaired LV relaxation in 43.5% patients and pseudonormal pattern in 32.3% patients). Following independent correlations were found: LVMI was related to PlGF, cholesterol, BNP, systolic blood pressure and serum creatinine. EN-RAGE correlated positively with left atrial diameter and inversely with E/A ratio. During the follow-up we found a significant increase in LVMI and left atrial diameter, whereas a significant decrease in LVEF was noted.

Conclusion

According to our data, PlGF is independently related to increased LV mass in CKD, whereas EN-RAGE is more likely related to diastolic dysfunction in this population.

【 授权许可】

   
2013 Peiskerová et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Luke RG: Chronic renal failure: a vasculopathic state. N Engl J Med 1998, 339(12):841-843.
• [2]Pateinakis P, Papagianni A: Cardiorenal syndrome type 4-cardiovascular disease in patients with chronic kidney disease: epidemiology, pathogenesis, and management. Int J Nephrol. 2011, 2011:938651.
• [3]Kalantar-Zadeh K, Shah A, Duong U, Hechter RC, Dukkipati R, Kovesdy CP: Kidney bone disease and mortality in CKD: revisiting the role of vitamin D, calcimimetics, alkaline phosphatase, and minerals. Kidney Int Suppl 2010, 117:S10-S21.
• [4]Covic A, Voroneanu L, Goldsmith D: The effects of vitamin D therapy on left ventricular structure and function - are these the underlying explanations for improved CKD patient survival? Nephron Clin Pract 2010, 116(3):187-195.
• [5]Ogunyankin KO: Assessment of left ventricular diastolic function: the power, possibilities, and pitfalls of echocardiographic imaging techniques. Can J Cardiol 2011, 27(3):311-318.
• [6]Nakamura T, Funayama H, Kubo N, Yasu T, Kawakami M, Momomura S, Ishikawa SE: Elevation of plasma placental growth factor in the patients with ischemic cardiomyopathy. Int J Cardiol 2009, 131(2):186-191.
• [7]Torry RJ, Tomanek RJ, Zheng W, Miller SJ, Labarrere CA, Torry DS: Hypoxia increases placental growth factor expression in human myocardium and cultured neonatal rat cardiomyocytes. J Heart Lung Transplant 2009, 28(2):183-190.
• [8]Pan P, Fu H, Zhang L, Huang H, Luo F, Wu W, Guo Y, Liu X: Angiotensin II upregulates the expression of placental growth factor in human vascular endothelial cells and smooth muscle cells. BMC Cell Biol 2010, 11:36. BioMed Central Full Text
• [9]Fialová L, Kalousová M, Soukupová J, Sulková S, Merta M, Jelínková E, Horejsí M, Srámek P, Malbohan I, Mikulíková L, Tesar V, Zima T: Relationship of pregnancy- associated plasma protein-a to renal function and dialysis modalities. Kidney Blood Press Res 2004, 27(2):88-95.
• [10]Kim JK, Park S, Lee MJ, Song YR, Han SH, Kim SG, Kang SW, Choi KH, Kim HJ, Yoo TH: Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN- RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis. Atherosclerosis 2012, 220(1):208-214.
• [11]Pilz S, Tomaschitz A, Friedl C, Amrein K, Drechsler C, Ritz E, Boehm BO, Grammer TB, März W: Vitamin D status and mortality in chronic kidney disease. Nephrol Dial Transplant 2011, 58(3):374-382.
• [12]Isakova T, Xie H, Yang W, Xie D, Anderson AH, Scialla J, Wahl P, Gutiérrez OM, Steigerwalt S, He J, Schwartz S, Lo J, Ojo A, Sondheimer J, Hsu CY, Lash J, Leonard M, Kusek JW, Feldman HI, Wolf M, Chronic Renal Insufficiency Cohort (CRIC) Study Group: Fibroblast growth factor 23 and risks of mortality and end-stage renal disease in patients with chronic kidney disease. JAMA 2011, 305(23):2432-2439.
• [13]Lang RM, Bierig M, Devereux RB, Flachskampf FA, Foster E, Pellikka PA, Picard MH, Roman MJ, Seward J, Shanewise JS, Solomon SD, Spencer KT, Sutton MS, Stewart WJ, Chamber Quantification Writing Group: Recommendations for chamber quantification: a report from the American society of Echocardiography’s guidelines and standards committee and the chamber quantification writing group, developed in conjunction with the European association of echocardiography, a branch of the European society of cardiology. J Am Soc Echocardiogr 2005, 18(12):1440-1463.
• [14]Chao TF, Wang KL, Chuang CF, Chen SA, Yu WC: Atrium electromechanical interval in left ventricular diastolic dysfunction. Eur J Clin Invest 2011, 42(2):117-122.
• [15]Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A: Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 2009, 10(2):165-193.
• [16]Levin A, Djurdjev O, Thompson C, Barrett B, Ethier J, Carlisle E, Barre P, Magner P, Muirhead N, Tobe S, Tam P, Wadgymar JA, Kappel J, Holland D, Pichette V, Shoker A, Soltys G, Verrelli M, Singer J: Canadian randomized trial of hemoglobin maintenance to prevent or delay left ventricular mass growth in patients with CKD. Am J Kidney Dis 2005, 46(5):799-811.
• [17]Cioffi G, Tarantini L, Frizzi R, Stefenelli C, Russo TE, Selmi A, Toller C, Furlanello F, de Simone G: Chronic kidney disease elicits excessive increase in left ventricular mass growth in patients at increased risk for cardiovascular events. J Hypertens 2011, 29(3):565-573.
• [18]Paoletti E, Bellino D, Gallina AM, Amidone M, Cassottana P, Cannella G: Is left ventricular hypertrophy a powerful predictor of progression to dialysis in chronic kidney disease? Nephrol Dial Transplant 2011, 26(2):670-677.
• [19]Soleimani A, Nasiri O, Nikoueinejad H, Yousefzade M, Foroozanfard F, Tabatabaizadeh M, Moraveji SA, Rajali M: Prognostic value of B-type natriuretic peptide for assessment of left ventricular function in patients with chronic kidney disease. Iran J Kidney Dis 2011, 5(4):242-247.
• [20]Henkel DM, Glockner J, Miller WL: Association of myocardial fibrosis, B-type natriuretic peptide, and cardiac magnetic resonance parameters of remodeling in chronic ischemic cardiomyopathy. Am J Cardiol 2011, 109(3):390-394.
• [21]Foley RN, Curtis BM, Randell EW, Parfrey PS: Left ventricular hypertrophy in new hemodialysis patients without symptomatic cardiac disease. Clin J Am Soc Nephrol 2010, 5(5):805-813.
• [22]Thadhani R, Appelbaum E, Chang Y, Pritchett Y, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson T, Audhya P, Andress D, Zhang W, Ye J, Packham D, Singh B, Zehnder D, Manning WJ, Pachika A, Solomon SD: Vitamin D receptor activation and left ventricular hypertrophy in advanced kidney disease. Am J Nephrol 2011, 33(2):139-149.
• [23]Accornero F, van Berlo JH, Benard MJ, Lorenz JN, Carmeliet P, Molkentin JD: Placental growth factor regulates cardiac adaptation and hypertrophy through a paracrine mechanism. Circ Res 2011, 109(3):272-280.
• [24]Roncal C, Buysschaert I, Gerdes N, Georgiadou M, Ovchinnikova O, Fischer C, Stassen JM, Moons L, Collen D, De Bock K, Hansson GK, Carmeliet P: Short-term delivery of anti-PlGF antibody delays progression of atherosclerotic plaques to vulnerable lesions. Cardiovasc Res 2010, 86(1):29-36.
• [25]Khurana R, Moons L, Shafi S, Luttun A, Collen D, Martin JF, Carmeliet P, Zachary IC: Placental growth factor promotes atherosclerotic intimal thickening and macrophage accumulation. Circulation 2005, 111(21):2828-2836.
• [26]Cassidy A: Potential role for plasma placental growth factor in predicting coronary heart disease risk in women. Arterioscler Thromb Vasc Biol 2009, 29(1):134-139.
• [27]Jaffe IZ, Newfell BG, Aronovitz M, Mohammad NN, McGraw AP, Perreault RE, Carmeliet P, Ehsan A, Mendelsohn ME: Placental growth factor mediates aldosterone-dependent vascular injury in mice. J Clin Invest 2010, 120(11):3891-3900.
• [28]Zakiyanov O, Kalousová M, Zima T, Tesař V: Placental growth factor in patients with decreased renal function. Ren Fail 2011, 33(3):291-297.
• [29]McQuarrie EP, Patel RK, Mark PB, Delles C, Connell J, Dargie HJ, Steedman T, Jardine AG: Association between proteinuria and left ventricular mass index: a cardiac MRI study in patients with chronic kidney disease. Nephrol Dial Transplant 2011, 26(3):933-938.
• [30]Canziani ME, Tomiyama C, Higa A, Draibe SA, Carvalho AB: Fibroblast growth factor 23 in chronic kidney disease: bridging the gap between bone mineral metabolism and left ventricular hypertrophy. Blood Purif 2011, 31(1–3):26-32.
• [31]Faul C, Amaral AP, Oskouei B, Hu MC, Sloan A, Isakova T, Gutiérrez OM, Aguillon-Prada R, Lincoln J, Hare JM, Mundel P, Morales A, Scialla J, Fischer M, Soliman EZ, Chen J, Go AS, Rosas SE, Nessel L, Townsend RR, Feldman HI, St John Sutton M, Ojo A, Gadegbeku C, Di Marco GS, Reuter S, Kentrup D, Tiemann K, Brand M, Hill JA, Moe OW, Kuro-O M, Kusek JW, Keane MG, Wolf M: FGF23 induces left ventricular hypertrophy. J Clin Invest 2011, 121(11):4393-4408.
• [32]Patel RK, Jardine AG, Mark PB, Cunningham AF, Steedman T, Powell JR, McQuarrie EP, Stevens KK, Dargie HJ, Jardine AG: Association of left atrial volume with mortality among ESRD patients with left ventricular hypertrophy referred for kidney transplantation. Am J Kidney Dis 2010, 55(6):1088-1096.
• [33]Custódio MR, Koike MK, Neves KR, dos Reis LM, Graciolli FG, Neves CL, Batista DG, Magalhães AO, Hawlitschek P, Oliveira IB, Dominguez WV, Moysés RM, Jorgetti V: Parathyroid hormone and phosphorus overload in uremia: impact on cardiovascular system. Nephrol Dial Transplant 2012, 27(4):1437-1445.
• [34]Chen SC, Su HM, Hung CC, Chang JM, Liu WC, Tsai JC, Lin MY, Hwang SJ, Chen HC: Echocardiographic parameters are independently associated with increased cardiovascular events in patients with chronic kidney disease. Nephrol Dial Transplant 2012, 27(3):1064-1070.
• [35]Hung MJ, Yang NI, Wu IW, Cheng CW, Liu PC, Chen SJ, Wu MS, Cherng WJ: Three-dimensional echocardiographic assessment of left ventricular remodeling in predialysis chronic kidney disease patients. J Nephrol 2011, 25(1):96-106.
• [36]Gawdzik J, Mathew L, Kim G, Puri TS, Hofmann Bowman MA: Vascular remodeling and arterial calcification are directly mediated by S100A12 (EN-RAGE) in chronic kidney disease. Am J Nephrol 2011, 33(3):250-259.
• [37]Mahajan N, Bahl A, Dhawan V: C-reactive protein (CRP) up-regulates expression of receptor for advanced glycation end products (RAGE) and its inflammatory ligand EN-RAGE in THP-1 cells: inhibitory effects of atorvastatin. Int J Cardiol 2010, 142(3):273-278.
• [38]Leonardis D, Basta G, Mallamaci F, Cutrupi S, Pizzini P, Tripepi R, Tripepi G, De Caterina R, Zoccali C: Circulating soluble receptor for advanced glycation end product (sRAGE) and left ventricular hypertrophy in patients with chronic kidney disease (CKD). Nutr Metab Cardiovasc Dis 2012, 22(9):748-755.
• [39]Lindsey JB, Cipollone F, Abdullah SM, McGuire DK: Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications. Diab Vasc Dis Res 2009, 6(1):7-14.
• [40]Zamboli P, De Nicola L, Minutolo R, Chiodini P, Crivaro M, Tassinario S, Bellizzi V, Conte G: Effect of furosemide on left ventricular mass in non-dialysis chronic kidney disease patients: a randomized controlled trial. Nephrol Dial Transplant 2011, 26(5):1575-1583.
• [41]Thadhani R, Appelbaum E, Pritchett Y, Chang Y, Wenger J, Tamez H, Bhan I, Agarwal R, Zoccali C, Wanner C, Lloyd-Jones D, Cannata J, Thompson BT, Andress D, Zhang W, Packham D, Singh B, Zehnder D, Shah A, Pachika A, Manning WJ, Solomon SD: Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: the PRIMO randomized controlled trial. JAMA 2012, 307(7):674-684.
• [42]Metz CE: Basic principles of ROC analysis. Semin Nucl Med 1978, 8(4):283-298.